Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.5 CHF | -0.86% | -0.62% | -0.37% |
May. 31 | Skan Group Boosts Interest in Belgian Unit Aseptic Technologies to 90% | MT |
Mar. 26 | Transcript : SKAN Group AG, 2023 Earnings Call, Mar 26, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.41 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.37% | 2B | - | ||
+75.69% | 12.57B | B- | ||
-24.68% | 7.34B | C+ | ||
+12.58% | 5.39B | D+ | ||
-16.63% | 4.84B | B | ||
+26.90% | 4.53B | - | ||
-22.26% | 3.91B | B- | ||
-22.99% | 2.91B | C | ||
+47.42% | 2.37B | C- | ||
+6.21% | 1.91B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SKAN Stock
- Ratings SKAN Group AG